VHIO Scientific Manager is a pioneer in translational research
news
Queen Sofía and Councillor Marina Geli assist at the opening ceremony
This research studied the action mechanisms of two drugs—lapatinib and trastuzumab—in combination for the treatment of HER2-positive breast cancer. Lapatinib is a molecule which, when combined with trastuzumab, neutralizes the activity of the HER2 receptor and improves the effect of the antibody
